Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic ...
The diagnosis of NETs is often delayed and approximately 10% to 20% of pediatric patients are diagnosed with metastatic disease. The approval was based on the NETTER-P trial, which evaluated Lutathera ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback